Fatty Liver Disease (FLD)

Introduction

Fatty liver disease (FLD) is a spectrum of liver disorders characterized by the accumulation of excess fat in the liver. FLD is increasingly recognized as the most common liver disorder in industrialized nations, closely linked to metabolic syndrome, obesity, type 2 diabetes, and dyslipidemia.

FLD has emerged as the leading cause of chronic liver disease worldwide, affecting about 30% of adults worldwide, a share that rose to about 38% in 2016–2019. The prevalence is significantly higher in individuals with obesity and diabetes: about 75% of people with obesity and about 65% of people with type 2 diabetes. The incidence of FLD is increasing, paralleling the global rise in obesity and type 2 diabetes. FLD affects both adults and children, with a growing concern for its impact on pediatric populations. Body shape is part of the picture: the firm, protruding beer belly is largely visceral fat, and in a genetic (Mendelian randomization) study, higher visceral fat mass was linked to roughly double the risk of fatty liver.

Pathogenesis

The pathogenesis of FLD is multifactorial and complex, involving a combination of genetic, environmental, and metabolic factors. The widely accepted “two-hit” hypothesis has been replaced by a more nuanced “multiple-hit” model. This model suggests that various factors act synergistically to promote liver fat accumulation and inflammation.

1. Deficiency of micronutrients: Choline (an essential nutrient, sometimes grouped with the B vitamins) is needed for the liver to export fat. A diet too low in choline does cause fatty liver: in people fed intravenously without choline, steatosis developed and reversed once choline was added. In most people, though, fatty liver is driven mainly by excess energy intake and insulin resistance, and low choline intake is one contributing factor.
2. Dysregulation of Hepatic Glucose Production: The liver plays a key role in maintaining glucose homeostasis by balancing glucose production and storage. In a healthy liver, insulin suppresses gluconeogenesis (the production of glucose). However, in the presence of fatty liver, this suppression becomes impaired, leading to increased hepatic glucose output despite elevated insulin levels, contributing to systemic insulin resistance.
3. Insulin resistance: Central to the pathogenesis of FLD, insulin resistance promotes lipolysis in adipose tissue, leading to increased free fatty acid (FFA) influx into the liver. The liver, unable to fully metabolize these FFAs, accumulates triglycerides.

This is how FLD and insulin resistance close a self-perpetuating cycle. The main lever for breaking it is “the fuel”: excess calories, especially from sugars and refined carbohydrates. Nutrient supply is the other part of the picture: the liver needs enough choline to package fat and send it out, and choline contributes to normal lipid metabolism and to the maintenance of normal liver function.

What is Causing Those Micronutrient Shortages?

1. Increased Demand of the Liver, for Catalysts (vitamins) and Reagents (minerals and amino acids) for its detoxification functions. Some of this work, such as methylation (deactivating substances so they can be removed from the body), draws on the same methyl donors, methionine and choline, so a heavier load of foreign substances from food, water and air may raise the demand.

2. Reduced Nutrient Density: Modern agricultural practices have multiplied crop yields from the same land through high-yield varieties and artificial fertilizers, primarily containing nitrogen (N), phosphorus (P), and potassium (K). While this boosts the size and mass of the plants, it results in crops that are primarily composed of energy but contain significantly fewer essential micronutrients. Depending on the specific nutrient and crop, some analyses report roughly 6–38% less of certain nutrients than in crops grown around 1950, a finding that is still debated. This includes reductions in essential micronutrients (like iron, zinc, and magnesium) and vitamins (such as vitamin C) in modern crops This phenomenon is often referred to as the dilution effect.

3. The damage caused on the Gut microbiota: can significantly impair the body’s ability to absorb essential micronutrients such as vitamins and minerals. The gut microbiota plays a crucial role in breaking down food, synthesizing vitamins and assisting in the absorption of minerals. Disruption of this microbial balance, often due to poor diet and antibiotics, or chronic illness, can lead to malabsorption. This reduction in nutrient uptake can contribute to deficiencies, affecting overall health, immunity, and metabolic function.

In short, compared to 60-70 years ago, the same amount of food may carry fewer micronutrients, which may be absorbed less well, while demand may be higher. Choline is a related problem: most adults eat less of it than the recommended adequate intake, and a low choline supply makes it harder for the liver to export fat.

This all gets worsen by a variety of factors like:

Oxidative stress: Excess FFAs undergo oxidation in hepatocytes, generating reactive oxygen species (ROS), which damage cellular structures and exacerbate inflammation.

Gut microbiota and endotoxins: Dysbiosis, or an imbalance in gut microbiota, may lead to increased intestinal permeability, allowing endotoxins (e.g., lipopolysaccharides) to enter the circulation and contribute to liver inflammation.

Genetic factors: Polymorphisms in genes such as PNPLA3, TM6SF2, and MBOAT7 have been associated with increased susceptibility to NAFLD and its progression

Clinical Manifestations

FLD is a silent disease, often asymptomatic in its early stages. It encompasses a spectrum ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC).

1. Non-alcoholic fatty liver (NAFL): Characterized by the accumulation of fat in hepatocytes without significant inflammation or fibrosis. It is generally considered benign but can progress to NASH.
2. Non-alcoholic steatohepatitis (NASH): Involves hepatocellular inflammation and varying degrees of fibrosis. NASH poses a higher risk of progression to cirrhosis and HCC.
3. Cirrhosis and hepatocellular carcinoma (HCC): In some cases, NASH progresses to cirrhosis, characterized by extensive fibrosis, impaired liver function, and increased risk of developing HCC.

Diagnostic Approaches

The diagnosis of FLD is typically based on clinical evaluation, blood samples and imaging studies.

Imaging: Ultrasonography is the most commonly used imaging modality for detecting hepatic steatosis. More advanced techniques, such as transient elastography (FibroScan) and magnetic resonance imaging-proton density fat fraction (MRI-PDFF), provide valuable information about liver stiffness and fat content.

1. Biomarkers: Several serum biomarkers and scoring systems, such as the NAFLD fibrosis score (NFS), FIB-4, and AST-to-platelet ratio index (APRI), can help assess the severity of fibrosis and the likelihood of NASH.
2. Liver biopsy: Although invasive, liver biopsy is the only definitive method for distinguishing between simple steatosis and NASH and for staging fibrosis.

Management and Treatment

The management of FLD focuses on treating the underlying metabolic disorders and preventing disease progression. The EU has now approved two medicines, resmetirom (2025) and semaglutide (2026), but only for the inflammatory form (MASH) with moderate to advanced fibrosis, not for simple fatty liver. For choline, the EU has authorised a narrower statement: it contributes to normal lipid metabolism and to the maintenance of normal liver function. If you are curious how much choline one serving of LiverGuard provides and what it is combined with, the full formula is on its page, meant to sit alongside the steps below, not to replace them or your doctor’s advice.

Weight loss through dietary changes and physical activity can be beneficial for the liver and overall health, especially in obese patients.

Prognosis and Complications

Though hepatic steatosis alone may not result in overt liver dysfunction, it creates a metabolic environment conducive to further liver and overall health injury.

Complications

Oxidative Stress and Mitochondrial Dysfunction

The accumulation of free fatty acids (FFAs) in hepatocytes leads to increased fatty acid oxidation, generating reactive oxygen species (ROS). ROS production overwhelms the liver’s antioxidant defenses, resulting in oxidative stress, causing Mitochondrial Damage and Lipid Peroxidation. Zinc is one of the nutrients that antioxidant defence depends on — as part of copper-zinc superoxide dismutase and through the induction of metallothionein — which is why zinc status becomes relevant once oxidative stress is the driving force.

Key Liver Functions Suppressed by Liver Fat Accumulation

The accumulation of fat in the liver disrupts several critical hepatic functions:

1. Glucose Metabolism:
   • Gluconeogenesis and Glycogen Storage: Hepatic steatosis impairs glucose regulation, contributing to hyperglycemia and increasing the risk of type 2 diabetes mellitus (T2DM).
2. Lipid Metabolism:
   • VLDL Secretion: The fatty liver actually exports more triglyceride-rich VLDL, which raises serum triglycerides and lowers HDL cholesterol (dyslipidemia), yet export reaches a ceiling and cannot keep pace with the fat coming in, so fat keeps accumulating.
3. Detoxification:
   • Ammonia Clearance: Impaired urea cycle function in advanced NAFLD can lead to hyperammonemia, resulting in hepatic encephalopathy.
   • Drug Metabolism: Most medicines pass through the liver, and a fatty liver can process some of them (and other xenobiotics) differently, which may change their effects. Do not stop or change prescribed medicines without talking to your doctor.
4. Protein Synthesis:
   • Clotting Factors and Albumin: In advanced disease (cirrhosis), reduced synthesis of coagulation proteins increases the risk of bleeding, while decreased albumin production contributes to edema and ascites.
5. Bile Production:
   • Fat Digestion and Vitamin Absorption: In advanced liver disease, impaired bile secretion can reduce the absorption of fat-soluble vitamins (A, D, E, K), leading to deficiencies.

Systemic Consequences of FLD

While the liver is the primary organ affected in FLD, fat deposition and the resultant inflammatory and metabolic disruptions have widespread consequences beyond the liver.

1. Cardiovascular Disease (CVD)

FLD is closely associated with cardiovascular diseases, which represent the leading cause of mortality in FLD patients. Key mechanisms include:

• Atherosclerosis: Systemic inflammation, oxidative stress, and dyslipidemia promote endothelial dysfunction and plaque formation in arteries.
• Hypertension and Heart Failure: Elevated blood pressure and impaired cardiac function are common in advanced FLD.

2. Type 2 Diabetes Mellitus (T2DM)

Insulin resistance is central to the pathogenesis of FLD, and as the disease progresses, it exacerbates systemic insulin resistance, increasing the risk of developing T2DM. Hepatic insulin resistance further impairs glucose metabolism, creating a vicious cycle between FLD and diabetes.

3. Chronic Kidney Disease (CKD)

FLD is an independent risk factor for CKD. Mechanisms include:

• Systemic Inflammation: Chronic inflammation and oxidative stress contribute to kidney damage.
• Endothelial Dysfunction: Shared risk factors like insulin resistance and hypertension promote renal dysfunction.

4. Endocrine Disorders

FLD is associated with a number of endocrine disorders, including:

• Polycystic Ovary Syndrome (PCOS): Insulin resistance links FLD to PCOS, a common endocrine disorder in women.
• Hypothyroidism: Thyroid dysfunction, particularly hypothyroidism, is more prevalent in FLD patients and may exacerbate metabolic disturbances.

5. Sleep Apnea

Obstructive sleep apnea (OSA) is frequently observed in FLD patients. The pathophysiological link is thought to involve shared risk factors, such as obesity, as well as systemic inflammation, which may contribute to airway collapse during sleep.

6. Malignancies

In addition to hepatocellular carcinoma (HCC), FLD has been associated with an increased risk of extrahepatic malignancies, including colorectal, breast, and pancreatic cancers. Chronic inflammation and altered immune surveillance are thought to underlie this increased cancer risk.

Conclusion

FLD is not merely a liver-specific disorder; it represents a systemic disease with far-reaching consequences. Fat deposition in the liver disrupts a range of hepatic functions, primarily through oxidative stress, inflammation, and insulin resistance. As FLD progresses, it not only impairs the liver’s ability to regulate metabolism, detoxify toxins, and synthesize essential proteins, but it also predisposes patients to a wide array of extrahepatic diseases, including cardiovascular disease, type 2 diabetes, chronic kidney disease, and various malignancies.

FLD has a variable prognosis, largely dependent on the amount of fat accumulated in the liver and the degree of fibrosis. While simple steatosis generally has a benign course, NASH progresses to cirrhosis in roughly 20% of patients over years to decades, with an increased risk of liver-related complications, including HCC. Cardiovascular disease (CVD) remains the leading cause of death in patients with FLD, highlighting the importance of managing associated metabolic disorders.

References

• Abenavoli, L., Milic, N., Di Renzo, L., et al. (2016). Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 22(31), 7006-7016. DOI: 10.3748/wjg.v22.i31.7006
• Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 24(7), 908-922. DOI: 10.1038/s41591-018-0104-9
• Targher, G., Day, C. P., & Bonora, E. (2010). Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine, 363(14), 1341-1350. DOI: 10.1056/NEJMra0912063
• Younossi, Z. M., Golabi, P., Paik, J. M., et al. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 77(4), 1335-1347. DOI: 10.1097/HEP.0000000000000004
• Quek, J., Chan, K. E., Wong, Z. Y., et al. (2023). Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 8(1), 20-30. DOI: 10.1016/S2468-1253(22)00317-X
• En Li Cho, E., Ang, C. Z., Quek, J., et al. (2023). Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut, 72(11), 2138-2148. DOI: 10.1136/gutjnl-2023-330110
• Tao, M., Zhou, G., Liu, J., et al. (2023). Visceral adipose tissue and risk of nonalcoholic fatty liver disease: A Mendelian randomization study. Clinical Endocrinology, 99(4), 370-377. DOI: 10.1111/cen.14953
• Buchman, A. L., Dubin, M. D., Moukarzel, A. A., et al. (1995). Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology, 22(5), 1399-1403. DOI: 10.1002/hep.1840220510
• Davis, D. R., Epp, M. D., & Riordan, H. D. (2004). Changes in USDA food composition data for 43 garden crops, 1950 to 1999. Journal of the American College of Nutrition, 23(6), 669-682. DOI: 10.1080/07315724.2004.10719409
• Fan, M. S., Zhao, F. J., Fairweather-Tait, S. J., et al. (2008). Evidence of decreasing mineral density in wheat grain over the last 160 years. Journal of Trace Elements in Medicine and Biology, 22(4), 315-324. DOI: 10.1016/j.jtemb.2008.07.002
• Fabbrini, E., Mohammed, B. S., Magkos, F., et al. (2008). Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology, 134(2), 424-431. DOI: 10.1053/j.gastro.2007.11.038
• Loomba, R., & Adams, L. A. (2019). The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology, 70(6), 1885-1888. DOI: 10.1002/hep.30946
• European Medicines Agency. Rezdiffra (resmetirom): EPAR. Conditional marketing authorisation issued 18 August 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/rezdiffra
• European Medicines Agency. Kayshild (semaglutide): EPAR. Conditional marketing authorisation issued 26 March 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/kayshild
• Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods (choline: normal lipid metabolism, maintenance of normal liver function, normal homocysteine metabolism). Official Journal of the European Union, L 136, 1-40.
• NIH Office of Dietary Supplements. Choline: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/

Related reading

• How dangerous is liver fat
• Insulin resistance and fatty liver
• Leaky gut and the gut-liver axis